Shilpa Medicare Limited — Important, 18-11-2024: General Updates

Shilpa Pharma Lifesciences Limited, a subsidiary of Shilpa Medicare Limited, has received a certificate of suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its active pharmaceutical ingredient (API), Octreotide. This synthetic peptide is crucial in treating conditions such as acromegaly and severe diarrhea associated with specific tumors. The approval marks a significant addition to Shilpa's peptide portfolio, reinforcing its commitment to high-quality standards in development and commercial production. The achievement is expected to enhance the company's competitive position in the global pharmaceutical market, offering potential growth opportunities for investors.